Sign in Subscribe
Cytology

MaxCyte's Cell Loading System Used in Groundbreaking Leukemia Trial

Strategic Insights

— 1 min read

A groundbreaking phase I/II clinical trial is underway to treat chronic lymphocytic leukemia (CLL) using an innovative immunotherapeutic approach. The trial, sponsored by the Center for Cell and Gene Therapy at Baylor College of Medicine and The Methodist Hospital, utilizes MaxCyte's MaxCyte GT cell loading system to create a personalized cell product that enhances the immune response against CLL cells. This treatment shows promise in overcoming the limitations of current CLL therapies.

Key Takeaways:

  • The trial is a non-randomized, open-label study assessing the safety of escalating doses of a cell product combining CD40 ligand (CD40L), interleukin 2 (IL-2), and each patient's own cells.
  • The MaxCyte GT system successfully transfects CLL cells with a high level of viability and efficiency, creating an autologous immunotherapeutic approach.
  • The trial protocol has been approved for treating 21 patients, with escalating doses administered at one to two week intervals for six treatments.
  • The primary endpoint of the study will be a decrease in CLL cell counts, indicating favorable activity.
  • Preliminary data is anticipated in 2005 and will be used to design a phase II trial to assess the efficacy of the immunotherapeutic approach.
  • MaxCyte's technology eliminates the use of viral vectors, overcoming significant regulatory issues raised by the FDA.
  • The trial has received a Master File containing supporting data for the MaxCyte cell loading system, which was referenced by Baylor for this study.
  • MaxCyte's MaxCyte GT system is a key component in the development of targeted cell therapies and accelerated drug discovery processes.

Statistics:

  • 21 patients will be treated in the trial.
  • The escalating doses of cell product will be administered at one to two week intervals for six treatments.
  • The study is non-randomized and open-label.
  • Preliminary data is anticipated in 2005.
  • The primary endpoint of the study is a decrease in CLL cell counts.

Sources:

  • MaxCyte, Inc. press release, August 23, 2004
  • Center for Cell and Gene Therapy at Baylor College of Medicine and The Methodist Hospital
  • Health & Medicine Week editors, via NewsRx.com & NewsRx.net, 2004
  • U.S. Food and Drug Administration (FDA) and FDA Recombinant Advisory Committee
  • FDA Center for Biologics Research and Review
  • MaxCyte, Inc.

Read more